Skip to content
Bomb Report – Lifestyle
Author:
Vor Biopharma
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
March 30, 2026
Vor Bio Announces $75 Million Private Placement with TCGX
March 27, 2026
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 23, 2026
←
Previous Page
1
2